Omarigliptin regulatory update

Merck submitted an NDA in Japan for omarigliptin to treat Type II diabetes. It is the first regulatory submission for the once-weekly oral dipeptidyl peptidase-4 ( DPP-4; CD26) inhibitor. Merck expe...